Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 6, No. 1-2, 2009
Issue release date: December 2008
Section title: Original Paper
Free Access
Neurodegenerative Dis 2009;6:23–28

Plasma Urate and Progression of Mild Cognitive Impairment

Irizarry M.C.a · Raman R.c, d · Schwarzschild M.A.a · Becerra L.M.c · Thomas R.G.c, d · Peterson R.C.e · Ascherio A.b · Aisen P.S.d
aDepartment of Neurology, Massachusetts General Hospital,and bDepartment of Epidemiology, Harvard School of Public Health, Boston, Mass., cDivision of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, and dDepartment of Neurosciences, University of California San Diego, San Diego, Calif., and eDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minn., USA
email Corresponding Author

Michael C. Irizarry, MD

WW Epidemiology, GlaxoSmithKline

5 Moore Drive, 17.2123

Research Triangle Park, NC 27709 (USA)

Tel. +1 919 483 7701, Fax +1 919 315 4947, E-Mail michael.c.irizarry@gsk.com

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Impaired antioxidant defenses are implicated in neurodegenerative disease. The plasma levels of urate, a water-soluble antioxidant, are reduced in Alzheimer’s disease (AD). Objective: We aimed to test the hypotheses that high plasma urate at baseline is associated with: (1) a reduced rate of conversion from mild cognitive impairment (MCI) to AD and (2) a lower rate of cognitive decline in MCI. Methods: Plasma urate was obtained at baseline from 747 participants in a 3-year, randomized, double-blind, placebo-controlled study of donepezil, vitamin E or placebo for delaying the progression of MCI to AD.The association between baseline urate and conversion from MCI to AD was examined by Cox proportional hazards regression. The relationship between baseline urate and cognitive change on the cognitive subscale of the Alzheimer’s Disease Assessment Scale was evaluated by longitudinal analysis. Results: Baseline plasma urate was not associated with the rate of conversion of MCI to AD. In the placebo arm, high plasma urate was related to a slower rate of cognitive decline over 3 years, although this was not reproduced in the other treatment arms. Conclusion: While plasma urate levels did not predict the progression of MCI to AD, high urate may be associated with a reduced rate of cognitive decline in MCI patients not treated with donepezil or vitamin E. The results support the investigation of biomarkers of antioxidant status as risk factors for cognitive decline in MCI.

© 2008 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 19, 2008
Accepted: May 26, 2008
Published online: November 05, 2008
Issue release date: December 2008

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.